{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:41:03Z","timestamp":1779925263723,"version":"3.53.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN_EU-380-5765"],"award-info":[{"award-number":["IN_EU-380-5765"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024809","name":"University of Nairobi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health Kenya"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Older people living with HIV (PWH) are disproportionately affected by an increasing burden of comorbidities. There are few clinical trials of switching antiretrovirals in this population, particularly in Africa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label randomized trial, virally suppressed PWH aged \u226560 years were randomized 1:1 to switch to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) or to continue their current antiretroviral regimen (CAR) at two sites in Kenya. Participants had bone mineral density (BMD) measurement at baseline, and at weeks 24 and 48. Calcium and vitamin D supplementation was provided to all participants beginning partway through the study because of high rates of osteoporosis identified at baseline. The primary endpoints were proportion of participants with plasma HIV-1 RNA of \u226550\u2005copies\/mL at week 48 using the US Food and Drug Administration snapshot algorithm, a non-inferiority margin of 4%, and the percentage change in the lumbar spine BMD at week 48. We report the primary efficacy, BMD and safety analysis at week 48. The study is continuing to week 96.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between March and July 2022, we enrolled 520 participants with 260 randomized to switch to B\/F\/TAF and 260 to continue CAR and were included in intention-to-treat analysis. At week 48, 1.9% (5\/260) of participants had HIV-1 RNA \u2265 50\u2005copies\/mL in the B\/F\/TAF arm and 2.7% (7\/260) in the CAR arm (treatment difference [95% CI], \u22120.8% [\u22123.4 to 1.8]), indicating non-inferiority. Change in lumbar spine BMD at week 48 was +2.18% in the B\/F\/TAF arm and 0.68% in the CAR arm (difference 1.51, CI .27\u20132.76, P .017). Treatment-related grade 3 or 4 adverse events were similar across arms (16.9% on B\/F\/TAF; 14.2% on CAR). Fifteen participants had grade 3 or 4 AEs leading to study drug discontinuation, all in the CAR arm due to declining kidney function. More participants on B\/F\/TAF developed incident dyslipidemia compared with participants on CAR (23% on B\/F\/TAF; 14% on CAR; P .015).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switch to B\/F\/TAF was non-inferior to CAR and safe in an African population aged \u226560 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf653","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:02:41Z","timestamp":1763643761000},"source":"Crossref","is-referenced-by-count":1,"title":["First-Line Switch to B\/F\/TAF for Treatment of HIV in Older Adults \u226560 Years in Kenya (the B\/F\/TAF-Elderly Study)"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-8792","authenticated-orcid":false,"given":"Loice Achieng","family":"Ombajo","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Therapeutics, University of Nairobi , Nairobi ,","place":["Kenya"]},{"name":"Center for Epidemiological Modelling and Analysis, University of Nairobi , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-1748","authenticated-orcid":false,"given":"Jeremy","family":"Penner","sequence":"additional","affiliation":[{"name":"Center for Epidemiological Modelling and Analysis, University of Nairobi , Nairobi ,","place":["Kenya"]},{"name":"Department of Family Practice, University of British Columbia , British Columbia, Vancouver ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-2948","authenticated-orcid":false,"given":"Joseph","family":"Nkuranga","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Therapeutics, University of Nairobi , Nairobi ,","place":["Kenya"]},{"name":"Center for Epidemiological Modelling and Analysis, University of Nairobi , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Omodi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Therapeutics, University of Nairobi , Nairobi ,","place":["Kenya"]},{"name":"Center for Epidemiological Modelling and Analysis, University of Nairobi , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Otieno","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Therapeutics, University of Nairobi , Nairobi ,","place":["Kenya"]},{"name":"Center for Epidemiological Modelling and Analysis, University of Nairobi , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared Ongechi","family":"Mecha","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Therapeutics, University of Nairobi , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wahome","sequence":"additional","affiliation":[{"name":"Comprehensive Care Center, Kenyatta National Hospital , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentius","family":"Ndinya","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jaramogi Oginga Odinga Teaching and Referral Hospital , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukia","family":"Aksam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jaramogi Oginga Odinga Teaching and Referral Hospital , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2557-4337","authenticated-orcid":false,"given":"Sanjay","family":"Bhagani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and HIV Medicine, Royal Free London Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Wafula","sequence":"additional","affiliation":[{"name":"National AIDS\/STI Control Program, Ministry of Health , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-5323","authenticated-orcid":false,"given":"Anton","family":"Pozniak","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, London School of Hygiene and Tropical Medicine , London ,","place":["UK"]},{"name":"Department of Sexual Health and HIV Medicine, Chelsea and Westminster Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Nyakoe","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mbagathi District Hospital , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the B\/F\/TAF-Elderly Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Wanjohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Onyango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foram","family":"Bhogayata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Oyoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Onywera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Atandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agatha","family":"Theuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beryl","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kamau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wanjiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Karuoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Ongubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Kiambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila Eshiwani","family":"Juliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Gekonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Kinyanjui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Chepchumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Morwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wauna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025112008022652800_ofaf653-B1","doi-asserted-by":"crossref","first-page":"e2327584","DOI":"10.1001\/jamanetworkopen.2023.27584","article-title":"Aging-related comorbidity burden among women and men with or at-risk for HIV in the US, 2008\u20132019","volume":"6","author":"Collins","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025112008022652800_ofaf653-B2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jgs.12695","article-title":"Polypharmacy, drug-drug interactions and potentially inappropriate medications in older HIV-infected adults","volume":"62","author":"Greene","year":"2014","journal-title":"J Am Geriatric Soc"},{"key":"2025112008022652800_ofaf653-B3"},{"key":"2025112008022652800_ofaf653-B4"},{"key":"2025112008022652800_ofaf653-B5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/MNH.0000000000000392","article-title":"Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug","volume":"27","author":"Chan","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025112008022652800_ofaf653-B6","first-page":"183","article-title":"A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population","volume":"7","author":"Chawla","year":"2018","journal-title":"ID Therapy"},{"key":"2025112008022652800_ofaf653-B7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/infdis\/jix202","article-title":"Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus\u2013infected middle-aged individuals compared with human immunodeficiency virus\u2013uninfected controls","volume":"216","author":"Kooij","year":"2017","journal-title":"J Infect Dis"},{"key":"2025112008022652800_ofaf653-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000002207","article-title":"Management of osteoporosis in patients living with HIV-A systematic review and meta-analysis","volume":"83","author":"Starup-Linde","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025112008022652800_ofaf653-B9","doi-asserted-by":"crossref","first-page":"e0233501","DOI":"10.1371\/journal.pone.0233501","article-title":"Bone fracture among people living with HIV: a systematic review and meta-regression of prevalence, incidence, and risk factors","volume":"15","author":"Pramukti","year":"2020","journal-title":"PLoS One"},{"key":"2025112008022652800_ofaf653-B10","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2025112008022652800_ofaf653-B11","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1016\/S2214-109X(22)00279-0","article-title":"Measuring kidney function: the voice of Africa","volume":"10","author":"Jiang","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2025112008022652800_ofaf653-B12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3851\/IMP3346","article-title":"The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis","volume":"25","author":"Baranek","year":"2020","journal-title":"Antivir Ther"},{"key":"2025112008022652800_ofaf653-B13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2018.07.010","article-title":"Risk of cardiovascular disease associated with exposure to Abacavir among individual with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies","volume":"52","author":"Dorjee","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2025112008022652800_ofaf653-B14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025112008022652800_ofaf653-B15","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide\u2013based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025112008022652800_ofaf653-B16","author":"Ambrosioni"},{"key":"2025112008022652800_ofaf653-B17"},{"key":"2025112008022652800_ofaf653-B18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/aid.2017.0203","article-title":"Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment","volume":"34","author":"DeJesus","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025112008022652800_ofaf653-B19","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"2025112008022652800_ofaf653-B20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2025112008022652800_ofaf653-B21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hiv.13741","article-title":"High prevalence of osteoporosis among virally suppressed older people (\u226560 years) living with HIV","volume":"26","author":"Penner","year":"2024","journal-title":"HIV Med"},{"key":"2025112008022652800_ofaf653-B22","author":"Food and Drug Administration"},{"key":"2025112008022652800_ofaf653-B23","author":"National Institutes of Health"},{"key":"2025112008022652800_ofaf653-B24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med"},{"key":"2025112008022652800_ofaf653-B25","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa2210005","article-title":"Second-line switch to dolutegravir for treatment of HIV infection","volume":"338","author":"Ombajo","year":"2023","journal-title":"N Engl J Med"},{"key":"2025112008022652800_ofaf653-B26","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"CID"},{"key":"2025112008022652800_ofaf653-B27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study","volume":"88","author":"Hagins","year":"2021","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"2025112008022652800_ofaf653-B28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international antiviral society\u2013USA panel","volume":"333","author":"Gandhi","year":"2024","journal-title":"JAMA"},{"key":"2025112008022652800_ofaf653-B29","author":"Waters"},{"key":"2025112008022652800_ofaf653-B30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025112008022652800_ofaf653-B31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/infdis\/jiaa125","article-title":"Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study","volume":"222","author":"Surial","year":"2020","journal-title":"J Infect Dis"},{"key":"2025112008022652800_ofaf653-B32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med"},{"key":"2025112008022652800_ofaf653-B33","doi-asserted-by":"crossref","first-page":"ofz414","DOI":"10.1093\/ofid\/ofz414","article-title":"Changes in body mass Index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"6","author":"Schafer","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025112008022652800_ofaf653-B34","doi-asserted-by":"crossref","first-page":"ofz472","DOI":"10.1093\/ofid\/ofz472","article-title":"Atherosclerotic cardiovascular disease risk profile of tenofovir alafenamide versus tenofovir disoproxil fumarate","volume":"7","author":"Huhn","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025112008022652800_ofaf653-B35","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1016\/S2352-3018(19)30195-X","article-title":"Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial","volume":"6","author":"Maggiolo","year":"2019","journal-title":"Lancet HIV"},{"key":"2025112008022652800_ofaf653-B36","doi-asserted-by":"crossref","first-page":"ofae007","DOI":"10.1093\/ofid\/ofae007","article-title":"Final 192-week efficacy and safety results of the ADVANCE trial, comparing 3 first-line antiretroviral regimens","volume":"11","author":"Sokhela","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025112008022652800_ofaf653-B37","author":"Glidden"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/11\/ofaf653\/65372230\/ofaf653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/11\/ofaf653\/65372230\/ofaf653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:02:45Z","timestamp":1763643765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf653\/8326865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf653","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,30]]},"article-number":"ofaf653"}}